Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

NewsGuard 100/100 Score

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion. The paper is currently available on the bioRxiv* preprint server while it undergoes peer review.

Genomic surveillance efforts that are used to track the global spread of SARS-CoV-2, a causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, pinpointed the emergence and rapid spread of several notable viral variants, also known as variants of concern.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

These variants have several mutations primarily in the receptor-binding domain (RBD) of the spike glycoprotein that protrudes from the viral surface and enables viral entry into cells by using its binding receptor on the human cells – angiotensin-converting enzyme 2 (ACE2).

Furthermore, RBD of the spike glycoprotein also represents a prime target of the humoral immune response and the region targeted by a majority of neutralizing antibodies. As a result, vaccines that are currently being used basically exploit this protein as their principal antigenic constituent.

Naturally, a problem with mutations within the RBD of the viral spike protein is that they may confer enhanced viral fitness and increased protein expression. This is the reason why a research group from the University of British Columbia in Canada and the University of Pittsburgh Medical Center in the US aimed to understand specific aspects of RBD mutations on common SARS-CoV-2 variants of concern.

Structural and biochemical experiments

By utilizing eleven SARS-CoV-2 spike glycoproteins with diverse complements of mutations, this research group led by Dr. Dhiraj Mannar and Dr. James W. Saville systematically appraised the contributions of major known variants of concern towards increasing ACE2 affinity and evading neutralizing antibodies.

This was primarily done with the use of cryogenic electron microscopy structural analysis; however, the researchers have also developed novel and hitherto unreported mutation combinations to explore the properties of variants that may possibly emerge in the future.

More specifically, spike proteins were engineered to express these RBD variant of concern mutations either as isolated traits or in different combinations. Subsequently, structural analysis with cryogenic electron microscopy in combination with biochemical assays has been used to analyze the effects.

ACE2 affinity and antibody binding effects

In short, their results have shown that individual SARS-CoV-2 RBD mutations may be categorized as resulting in either increased affinity for the ACE2 receptor alone, reduced ACE2 affinity and reduced antibody binding or a concurrent increase in ACE2 affinity and reduced antibody binding. However, these mutations can be combined with preserved individual effects.

It has to be noted that the majority of developed human-derived neutralizing antibodies can bind the RBD with footprints that span at least one of the positions corresponding to RBD mutation in variants of concern, which will be an important consideration in developing future treatment modalities.

The study has also shown that novel combinations of RBD mutations are able to retain antibody evasive properties when tested for antibody binding with a panel of monoclonal antibodies.

Elucidating evolutionary trajectory

“Overall, our findings suggest that the emergence of new SARS-CoV-2 variant spikes can be rationalized as the result of mutations that confer either increased ACE2 affinity, increased antibody evasion, or both, providing a framework to dissect the molecular factors that drive variant of concern evolution”, emphasize study authors in this bioRxiv paper.

Although we have focused the present study on RBD mutations present within variants of concern, it is possible that mutations elsewhere in the spike glycoprotein (particularly in the N-terminal domain) also play a significant role in antibody evasion and may affect ACE2 binding”, they caution.

With only several small exceptions, these results that describe the effects on ACE2 binding and antibody evasion as a result of RBD mutations in the tested SARS-CoV-2 variants of concern are highly in agreement with other recently published scientific reports.

Moreover, the study implies that RBD evolution basically follows a trajectory aimed towards a concomitant increase of receptor affinity and reduction of neutralizing antibody binding. Future studies will be needed to further elucidate these pertinent aspects of SARS-CoV-2 infection.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 12 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2023, April 12). Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding. News-Medical. Retrieved on May 30, 2024 from https://www.news-medical.net/news/20210830/Study-reveals-how-SARS-CoV-2-variants-of-concern-modulate-receptor-and-antibody-binding.aspx.

  • MLA

    Meštrović, Tomislav. "Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding". News-Medical. 30 May 2024. <https://www.news-medical.net/news/20210830/Study-reveals-how-SARS-CoV-2-variants-of-concern-modulate-receptor-and-antibody-binding.aspx>.

  • Chicago

    Meštrović, Tomislav. "Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding". News-Medical. https://www.news-medical.net/news/20210830/Study-reveals-how-SARS-CoV-2-variants-of-concern-modulate-receptor-and-antibody-binding.aspx. (accessed May 30, 2024).

  • Harvard

    Meštrović, Tomislav. 2023. Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding. News-Medical, viewed 30 May 2024, https://www.news-medical.net/news/20210830/Study-reveals-how-SARS-CoV-2-variants-of-concern-modulate-receptor-and-antibody-binding.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 1 trial for EBC-129 progresses into dose expansion